Tumori Journal Abstract Book - October 2020 - 92

92	
Material (Patients) and Methods: We reviewed all the
clinical files of PC pts' visits performed from March 1st to
April 30th, 2020 in the University Hospital of Pisa. We
analyzed the demographic characteristics, the comorbidities, the type of hormonal therapy pts received, the incidence of SARS-CoV-2 and the related lethality rate.
Results: 132 pts with PC had face-to-face or telemedicine
visits in the considered period. The median age was 76
(range 52-91), the mean age 75.44. The median number of
comorbidites was 2 (range 0-6). 115 (87.12%) pts received
LHRH analogue, 17 (12.88%) pts received LHRH analogue in combination with an anti-androgen. One pt had a
confirmed SARS-CoV-2 infection (0.76%), other 2 pts
(1.52%) had a clinical and/or radiological suspicion of
SARS-CoV2 infection, but no PCR confirmation. One of
these three pts (0.76%) died of ARDS (the considered pt
had no PCR confirmation of SARS-CoV-2).
Conclusions: In our population, living in a high-incidence
area for SARS-CoV2 infection, though being composed
by elderly with a discrete number of comorbidities, the
incidence rate was quite low, as well as the lethality rate,
corroborating the data published in the literature.

D51
Clinical course and outcomes of
COVID-19 in Cancer Patients: early
result from "onCOVID-19" study
Di Noia V.1, Squadroni M.1, Barile R.1, D'Aveni A.1, Liguori A.1, Brena
F.1, Dalto S.1, Di Cintio D.1, Sauta M.G.1, Ceresoli G.L.1, Salvini P.1,
Beretta G.D.1
1

Oncologia Medica, Humanitas Gavazzeni, Bergamo

Background: Cancer patients (pts) are considered at
higher risk of SARS-CoV-2 infection and more serious
COVID-19 illness compared to the general population. We
present the early results of the "onCOVID-19" study
exploring clinical course and outcomes of SARS-CoV-2
infection in cancer pts.
Methods: In this observational study, we collected clinical
data of pts referred to our institution with histologically
confirmed diagnosis of solid cancer and COVID-19 from
Feb 1 to May 20,2020. COVID-19 diagnosis was laboratory or radiologically confirmed or clinically suspected for
suggestive symptoms, including fever (>37,5°C) and/or
respiratory tract symptoms, without any other causes.
Univariate and multivariate analyses were performed to
explore the risk factors associated with severe events
defined as hospitalization, admission to an intensive care
unit, mechanical ventilation or death.
Results: Of the 64 pts enrolled, 35 referring to our
Oncology Unit were analysed; the remaining 29, treated
for cancer in other institutions, will be included in the analysis after data completion. Pts characteristics: male/female

Tumori Journal 106(2S)
(63/37%), current or former/never smokers (76/24%);
stage IV/III (83/17%); median age 63 (47-86) years. Lung
was the most frequent site of primary tumor (43%) or
metastases (37%). Out 26 (74%) pts on active anti-tumor
treatment, 6 (23%) received immune checkpoint inhibitors
(ICI). Most common symptoms were fever (40%), shortness of breath (34%) and cough (23%); lymphopenia
(<1000/mm3) was found in 5/15 (33%) tested pts. The
diagnosis of COVID-19 was only clinical suspected in 2
(6%) cases and confirmed by RT-PCR or imaging (ground
glass opacity and/or patchy consolidation) in 11 (31%) and
31 (88%) pts, respectively. An anti-microbial (antibiotics,
antiretroviral drugs, plasma therapy) treatment was administrated in 19 (54%) pts; oxygen supplementation was
required in 11 (31%) pts. Eleven (31%) pts had severe
events, death occurred in 7 (20%) cases. Higher risk for
developing severe events was associated with active treatment (RR 4.03, 95%CI 1.8-8.9,p=0.007) and lymphopenia
(RR 4.0, 95%CI 1.1-14, p=0.007).
Conclusions: Early results of our ongoing study confirmed the vulnerability of cancer pts to COVID-19.
Although the small sample size, treatment with ICI and
lymphopenia seem to be risk factors for death and severe
events. Waiting for final results, screening cancer pts for
infection should be advisable before starting immunotherapy or in case of lymphopenia.

D52
COVID-19: Triage Strategies for
Patients Management in "S.
Timoteo" Hospital-Termoli
Rocchia N.1, Sciarretta G.2, Farina P.3, D'Addario D.3, Tartaglione P.1,
Santoro T.1, Corradi R.1, Olivieri M.1, Sorella A.1, Licursi M.1, D'Uva
R.1, Moio P.1, Carrozza F.3
1

First AID/ER S. Timoteo Hospital, Termoli; 2Medicine Internal S. Timoteo
Hospital, Termoli; 3Oncologic D.H. S. Timoteo Hospital, Termoli

Background: On 11 February 2020, the WHO declared
the existence of a new viral disease, causing a severe acute
respiratory syndrome-Coronavirus-2 (SARS-Cov-2). In
Molise, two of the first cases reported were the S. Timoteo
hospital of Termoli. On March 5, the hospital closes both
routine and emergency/emergency activities until March.
At the reopening, a two-tier triage started and from March
to May 2020 we collected data to understand the needs of
the population for access to the hospital during the
pandemic.
Methods: Two triage tents were set up at the entrance for
the wards and for access to the emergency room.
Oncologists performed an internal triage for their patients.
Those who had been in high-risk regions were admitted
only after quarantine or a swab. Other measures: pre-triage
phone, access to accompanying persons and visitors was
Tumori Journal Abstract Book - October 2020

Table of Contents for the Digital Edition of Tumori Journal Abstract Book - October 2020
